1. Home
  2. ARVN vs NWAX Comparison

ARVN vs NWAX Comparison

Compare ARVN & NWAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.27

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Logo New America Acquisition I Corp. Class A Common Stock

NWAX

New America Acquisition I Corp. Class A Common Stock

N/A

Current Price

$10.08

Market Cap

505.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ARVN
NWAX
Founded
2015
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
505.0M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
ARVN
NWAX
Price
$8.27
$10.08
Analyst Decision
Buy
Analyst Count
19
0
Target Price
$15.05
N/A
AVG Volume (30 Days)
711.6K
187.4K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
1.70
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.97
$9.68
52 Week High
$14.22
$10.34

Technical Indicators

Market Signals
Indicator
ARVN
NWAX
Relative Strength Index (RSI) 38.71 30.26
Support Level $7.90 $10.06
Resistance Level $8.40 $10.17
Average True Range (ATR) 0.32 0.02
MACD -0.13 -0.01
Stochastic Oscillator 11.88 16.67

Price Performance

Historical Comparison
ARVN
NWAX

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About NWAX New America Acquisition I Corp. Class A Common Stock

New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.

Share on Social Networks: